Reports Q3 revenue from Caribou’s (CRBU) licensing and collaboration agreements was $23.7M for the three months ended September 30 compared to $3.3M for the same period in 2022. The increase was primarily due to $21.5M in revenue recognized under the AbbVie Collaboration (ABBV) and License Agreement, including $20.8 M of revenue recognized upon termination of this agreement as previously disclosed, which was the remaining deferred revenue balance from AbbVie’s $30M upfront payment in February 2021. Caribou had $396.7M in cash, cash equivalents, and marketable securities as of September 30 compared to $317M as of December 31 . This amount includes the approximately $134.4 M in net proceeds from the Company’s underwritten public offering and the $25M equity investment from Pfizer. Caribou expects its cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plan into Q4 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRBU:
- Caribou Biosciences appoints Sundar Jagannath to Scientific Advisory Board
- Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
- Caribou Biosciences to Participate in Upcoming Investor Conferences
- Caribou Biosciences initiated with an Outperform at Evercore ISI
- Caribou Biosciences announces FDA clearance of IND application for CB-012